---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-22-007386"
form_type: "8-K"
ticker: "AGPU"
cik: "0001446159"
company_name: "Axe Compute Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:42:14.165434+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Predictive Oncology Q3 revenue $455.8K (+45% YoY); appoints new CEO Raymond Vennare

## Summary
- Q3 revenue $455,827, up 45% from $313,663 in Q3 2021; gross margin improved to 76% from 65%.
- Net loss for nine months $17.8M vs $11.9M year ago, including $7.2M goodwill impairment for zPREDICTA.
- Raymond F. Vennare appointed CEO and Chairman; he has 30+ years biotech experience.
- R&D expenses down 50% to $116,763; G&A up to $3.29M due to acquisition and CEO retirement costs.
- Cash and equivalents $25.4M at Sept 30, 2022.

## SEC filing metadata
- accession: 0001171843-22-007386
- form_type: 8-K
- ticker: AGPU
- cik: 0001446159
- company_name: Axe Compute Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446159/000117184322007386/0001171843-22-007386-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446159/000117184322007386/f8k_111022.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-22-007386
- JSON: https://secwatch.observer/filing/0001171843-22-007386.json
- Plain text: https://secwatch.observer/filing/0001171843-22-007386.txt

## Key facts
- Earnings Releases
  Axe Compute Inc. reported third quarter ended September 30, 2022 results: revenue $455,827.
  - Period: third quarter ended September 30, 2022
  - Revenue: $455,827
  - Result: reported results
  source text: issues surrounding the therapeutic use of human tissue and cells. Q3 2022 Financial results The consolidated reportable segments of Predictive Oncology’s recognized revenue is $455,827 for the quarter, which has increased from $313,663 to the comparative three-month period of 2021, which depicts a revenue growth of 45%. Helomics reported an improvement in its
  evidence_url: https://www.sec.gov/Archives/edgar/data/1446159/000117184322007386/0001171843-22-007386-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.